Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study

Leuk Res. 2020 Jul:94:106368. doi: 10.1016/j.leukres.2020.106368. Epub 2020 May 11.

Affiliations

¹ Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA. Electronic address: gegeorge@mcw.edu.
² Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
³ Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI, USA.

PMID: 32442786
DOI: 10.1016/j.leukres.2020.106368

No abstract available

Publication types

Clinical Trial
Letter
Observational Study

MeSH terms

Adult
Aged
Antithrombins / administration & dosage*
Asparaginase / administration & dosage*
Female
Humans
Male
Middle Aged
Polyethylene Glycols / administration & dosage*
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / complications
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Retrospective Studies
Venous Thrombosis* / drug therapy
Venous Thrombosis* / etiology

Substances

Antithrombins
Polyethylene Glycols
pegaspargase
Asparaginase